Skip to main content

Table 1 Clinic and pathological characteristics and IHC results of 156 early stage IDCs

From: E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis

Characteristics No. of patients (N = 156) (%)
Age (years, mean ± SD) 52.8 ± 12.0
Histologic grade
 I 13 (8.3)
 II 107 (68.6)
 III 36 (23.1)
Tumor stage
 T1 77 (49.4)
 T2 79 (50.6)
Nodal stage
 Negative 96 (61.5)
 Positive 60 (38.5)
TNM stage
 I 50 (32.1)
 II 106 (67.9)
E-cad
 Negative/low 27 (17.3)
 Positive 129 (82.7)
ER
 Negative 52 (33.3)
 Positive 104 (66.7)
PR
 Negative 82 (52.6)
 Positive 74 (47.4)
HER2
 Negative 129 (82.7)
 Positive 27 (17.3)
Ki67
 Negative 40 (25.6)
 Positive 116 (74.4)
Molecular subtypes
 Luminal A 30 (19.2)
 Luminal B 74 (47.4)
 HER2-enriched 14 (9.0)
 TNBC 38 (24.4)
  1. IHC immunohistochemistry, IDC invasive ductal carcinoma of the breast, TNBC triple-negative breast cancer